Atreca (BCEL)
(Delayed Data from OTC)
$0.09 USD
0.00 (3.95%)
Updated Jun 7, 2024 10:29 AM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Atreca, Inc. [BCEL]
Reports for Purchase
Showing records 81 - 100 ( 159 total )
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Highly Anticipated ATRC-101 Phase 1b Results Arriving This Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Efficacy and Biomarker Update of the Lead Program against Solid Tumors
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Initial Data for ATRC-101 in July; Next Target Announced
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; ATRC-101 First Data in 1H21 Represents Critical Driver
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways from 2021 AACR Virtual Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Takeaways from Our Covered Companies at the 33rd ROTH Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Initial Data Look Ahead for ATRC-101
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
You Are Invited to Our Virtual 33rd Annual ROTH Conference on March 15-17, 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
First In Human Data Mid-Year; Is There Efficacy Against Certain Tumors?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; Almost There; ATRC-101 Initial Data on the Horizon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J